Company news
HLS Therapeutics, Inc. news in 2018
HLS Therapeutics, Inc.'s news releases, calls and decks from 2018, newest first.
HLS Therapeutics Announces Q3 2018 Financial Results
November 15, 2018
HLS Therapeutics Announces that Amarin's Vascepa ® (icosapent ethyl) Demonstrates 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attack and Stroke in REDUCE-IT(TM), which Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite Endpoint
November 12, 2018
HLS Therapeutics to Host 2018 Third Quarter Results Conference Call
November 1, 2018
HLS Therapeutics Announces that Amarin's REDUCE-IT(TM) Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint
September 24, 2018
HLS Therapeutics Appoints Tim Hendrickson as CFO
September 6, 2018
HLS Therapeutics Announces Grant of Stock Options
August 22, 2018
HLS Therapeutics Announces Q2 2018 Financial Results
August 15, 2018
HLS Therapeutics to Host 2018 Second Quarter Results Conference Call
July 30, 2018
HLS Therapeutics to Host Annual Shareholder Meeting
June 15, 2018
HLS Therapeutics Enters into Automatic Share Purchase Plan
May 30, 2018
HLS Therapeutics Announces Q1 2018 Financial Results
May 16, 2018
HLS Therapeutics Announces Normal Course Issuer Bid
May 9, 2018
HLS Therapeutics to Host 2018 First Quarter Results Conference Call
May 9, 2018
HLS Appoints Ryan Lennox as General Counsel
May 7, 2018
HLS Therapeutics Announces Partial Redemption of Preferred Shares
April 26, 2018
HLS to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference
April 20, 2018
HLS Therapeutics Announces Fiscal 2017 Financial Results
March 29, 2018
HLS Therapeutics to Host 2017 Fourth Quarter and Year End Results Conference Call
March 19, 2018